🎉 M&A multiples are live!
Check it out!

Provexis Valuation Multiples

Discover revenue and EBITDA valuation multiples for Provexis and similar public comparables like Sanofi India, Abbott India, and Procter & Gamble Health.

Provexis Overview

About Provexis

Provexis PLC is a British food company. It is engaged in developing and licensing the Fruitflow, which is patented, natural, breakthrough ingredient which helps with platelet aggregation. Fruitflow reduces the propensity for aberrant blood clotting, typically associated with cardiovascular disease, which can result in heart attack and stroke. The extract is available in two formats, a syrup and a powder, and it can be included in a broad range of food, beverage and dietary supplement formats.


Founded

2004

HQ

United Kingdom of Great Britain and Northern Ireland
Employees

2

Website

provexis.com

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$14.5M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Provexis Financials

Provexis has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Provexis achieved revenue of $1.0M and an EBITDA of -$0.8M.

Provexis expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Provexis valuation multiples based on analyst estimates

Provexis P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $0.5M $1.0M XXX XXX XXX
Gross Profit $0.5M $0.4M XXX XXX XXX
Gross Margin 97% 37% XXX XXX XXX
EBITDA -$0.5M -$0.8M XXX XXX XXX
EBITDA Margin -108% -75% XXX XXX XXX
Net Profit -$0.3M -$0.5M XXX XXX XXX
Net Margin -58% -48% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Provexis Stock Performance

As of April 15, 2025, Provexis's stock price is GBP 0 (or $0).

Provexis has current market cap of GBP 11.7M (or $15.1M), and EV of GBP 11.3M (or $14.5M).

See Provexis trading valuation data

Provexis Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$14.5M $15.1M XXX XXX XXX XXX n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Provexis Valuation Multiples

As of April 15, 2025, Provexis has market cap of $15.1M and EV of $14.5M.

Provexis's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Provexis's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Provexis and 10K+ public comps

Provexis Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $14.5M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA n/a XXX XXX XXX
P/E n/a XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF n/a XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Provexis Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Provexis Valuation Multiples

Provexis's NTM/LTM revenue growth is n/a

Provexis's revenue per employee for the last fiscal year averaged $0.5M, while opex per employee averaged $0.6M for the same period.

Over next 12 months, Provexis's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Provexis's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Provexis and other 10K+ public comps

Provexis Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 106% XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 43% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee $0.5M XXX XXX XXX XXX
Opex per Employee $0.6M XXX XXX XXX XXX
S&M Expenses to Revenue 8% XXX XXX XXX XXX
G&A Expenses to Revenue 50% XXX XXX XXX XXX
R&D Expenses to Revenue 38% XXX XXX XXX XXX
Opex to Revenue 111% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Provexis Public Comps

See public comps and valuation multiples for Nutraceuticals & Cosmeceuticals comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
SynBiotic XXX XXX XXX XXX XXX XXX
Mega Lifesciences XXX XXX XXX XXX XXX XXX
Procter & Gamble Health XXX XXX XXX XXX XXX XXX
Abbott India XXX XXX XXX XXX XXX XXX
Sanofi India XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Provexis M&A and Investment Activity

Provexis acquired  XXX companies to date.

Last acquisition by Provexis was  XXXXXXXX, XXXXX XXXXX XXXXXX . Provexis acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Provexis

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Provexis

When was Provexis founded? Provexis was founded in 2004.
Where is Provexis headquartered? Provexis is headquartered in United Kingdom of Great Britain and Northern Ireland.
How many employees does Provexis have? As of today, Provexis has 2 employees.
Who is the CEO of Provexis? Provexis's CEO is Mr. Ian Ford.
Is Provexis publicy listed? Yes, Provexis is a public company listed on LON.
What is the stock symbol of Provexis? Provexis trades under PXS ticker.
When did Provexis go public? Provexis went public in 2004.
Who are competitors of Provexis? Similar companies to Provexis include e.g. SynBiotic, Mega Lifesciences, Procter & Gamble Health, Abbott India.
What is the current market cap of Provexis? Provexis's current market cap is $15.1M
What is the current revenue growth of Provexis? Provexis revenue growth between 2023 and 2024 was 106%.
Is Provexis profitable? Yes, Provexis is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.